The abstract is read at the publisher; the summary is JClub's.
In rheumatoid arthritis, anti-TNF plus anti-interleukin 6 receptor therapy is highly complementary, linked to CD14+ monocytes, and outperforms monotherapy in a collagen-induced arthritis mouse model.
- Why it matters: Primary non-response limits targeted therapy for immune-mediated inflammatory diseases, and the huge space of possible drug pairs makes rational prioritization difficult.
- What they did: MNRS analyzes longitudinal blood transcriptomic data from six IMIDs receiving different targeted therapies to rank complementary and potentially incompatible drug combinations.
- The result: Longitudinal patient signatures guide combination selection, and in rheumatoid arthritis, single-cell localization and mouse validation support moving this pair into clinical testing.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.